tbuckley/cabot-search huggingface dataset:
Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs.
Authors: K. Webber, D. Goldstein, B. K. Bennett, F. M. Boyle, P. L. De Souza, N. Wilcken, M. Friedlander, A. R. Lloyd
Journal: Journal of Clinical Oncology (2010)

9047 Background: We have previously reported a post-cancer fatigue (PCF) case rate of 24% post surgery, 42% at end-treatment, 19% at 6 months (mo), and 14% at 12 mo in a prospective cohort of over 200 women with early stage breast cancer, with approximately half having comorbid psychological disorder (Psych) at each time point. We now examine rates of health care utilization (HCU) and perceived health care needs (PHCN) and their associations with fatigue and Psych disorders. Methods: Structured interviews and self-report questionnaires identified PCF and Psych; HCU by self-report of number of visits to medical, mental health and complementary and alternative medicine (CAM) practitioners; PHCN by the Perceived Need for Care Questionnaire (PCNQ). Predictors of HCU were sought by linear regression, while PCNQ data was assessed by contingency analysis. Results: Data from 206 women (mean age 53 years, range 26-82) followed to 12 mo post therapy. Predictors of increased HCU were Psych at end-treatment (p = 0.015) and PCF at 6 mo (p = 0.003), with a trend for Psych at 6 mo (p = 0.088). The only significant predictor of CAM visits was Psych at 6 mo (p = 0.04). Women with PCF at 6 mo were more likely to report unmet needs for help with physical symptoms (25% vs. 4.9%, p = 0.008), physical therapies (40% vs. 9.9%, p = 0.02), counseling (15% vs. 1.4%, p = 0.014) and assistance with work (15% vs. 2.9%, p = 0.042). Persistent Psych was not a significant determinant of perceived unmet health care needs. Conclusions: Our results suggest that both persistent fatigue and psychological distress are drivers of health care utilization. The finding that psychological distress predicts CAM utilization warrants further study. That women with prolonged PCF have higher unmet needs suggests appropriate targeted educational and therapeutic interventions are required. Persistent PCF at 6 mo Persistent Psych at 6 mo 1 or more visits in previous month Yes No Yes No Medical 88% 89% 100% 88% Mental health 33% 10% 39% 11% Allied health 55% 33% 31% 36% CAM 42% 22% 31% 23% Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline, Merck, Novartis, Pfizer, Roche Novartis Amgen, Novartis, Roche
Clinical Significance of Serum Concentration of L-Kynurenine for Peripheral T-Cell Lymphoma, not Otherwise Specified
Authors: Yuhei Shibata, Nobuhiko Nakamura, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Takeshi Hara, Hisashi Tsurumi, Hisataka Moriwaki
Journal: Annals of Oncology (2014)
Correlation of clinical outcome with natural killer (NK) response to an anti-cancer, dendritic cell-based vaccine
Authors: M. Morse, T. Osada, A. Hobeika, S. Chui, T. Clay, H. K. Lyerly
Journal: Journal of Clinical Oncology (2005)

2585 Background: Cancer vaccines have generally been developed to activate antigen-specific T cell responses, but few studies have attempted to evaluate the non-specific, yet potentially clinically-relevant, NK response to immunization. We hypothesized that the NK response would predict clinical benefit in immunized patients. Methods: In a phase I clinical trial of a vaccine consisting of autologous dendritic cell (DC) loaded with a fowlpox vector encoding CEA (rF-CEA(6D)-TRICOM, we measured CEA-specific immune responses by ELISPOT assay and reported increases in 12/14 patients (Proc ASCO2004, abst 2508). Using archived peripheral blood specimens (n=9) from before and after all immunizations, we measured CD3-CD56+ NK% and NK cytolytic activity against the NK target K562. These data were compared with the clinical outcome of the patients. Results: There were no differences in the percentage of NK cells or NK markers NKG2A, NKG2C, NKG2D before or after immunization. In contrast, NK cytolytic activity increased in 4 patients (range 2.5 to 5 times greater lytic activity), was stable in 2 and decreased in 3. When patients were grouped by clinical activity (stable disease/no evidence of disease (n=5) versus progressive disease (N=4) at three months), we observed that the majority of those with stable disease/no evidence of disease had increases in their NK activity (Chi Square, P= 0.0163). The NK results predicted more closely the clinical outcome than did T cell responses (Chi Square, P=NS). Conclusions: NK responses following immunization with a dendritic cell vaccine are associated with clinical benefit as indicated by a lack of progressive disease. Monitoring of NK response during vaccine studies should be routinely performed. No significant financial relationships to disclose.
Abstract 15663: The Clinical Impact of Early Invasive Strategy on Non-ST-Segment Elevation Myocardial Infarction According to the Time-Varying Patterns of Cardiac Biomarker
Authors: Han-Young Jin, Dong-Soo Kim, Dae-Kyeong Kim, Jae-Sik Jang, Jeong-Sook Seo, Yeo-Jeong Song, Doo-Il Kim, Dong-Kie Kim, Ki-Hun Kim, Tae-Hyun Yang, Sang-Hoon Seol, Guang-Won Seo, Pil Sang Song, Ju-Il Yang, Ho-Young Lee
Journal: Circulation (2013)

Background: The clinical benefit of early invasive strategy in patients with non-ST-segment elevation myocardial infarction (NSTEMI) is still left uncertain. We sought to evaluate the clinical impact of early invasive strategy on NSTEMI patients according to the time-varying patterns of cardiac biomarker. Methods: This trial included 336 consecutive NSTEMI patients received percutaneous coronary intervention (PCI), and they were classified into two groups according to the changing pattern of cardiac biomarkers at first follow-up assessment: group I: rising pattern of both CK-MB and troponin I (n=164), group II: falling pattern of CK-MB and/or troponin I (n=172). The primary endpoint was 12-month major cardiac and cerebrovascular events (MACCE). We compared incidence of MACCE between early (<12 hours after arrival) and delayed (≥12 hours) PCI in each group. Results: There were no statistically significant differences of baseline characteristics between group I and II. The rates of 12-month MACCE were not d...
Ovarian and Steroidal Influences on Neuroendocrine Aging Processes in Female Rodents*
Authors: CALEB E. FINCH, LEDA S. FELICIO, CHARLES V. MOBBS, JAMES F. NELSON
Journal: Endocrine Reviews (1984)

SOME MAMMALIAN aging processes involve effects of steroids on the brain and pituitary. An ovarydependent, neuroendocrine aging syndrome of laboratory rats and mice is described in this article. This syndrome can be attenuated during aging by chronic ovariectomy and can be prematurely induced in young rodents by sustained exposure to estradiol (E2). The limited follicular stock in the ovary is proposed to be a major pacemaker of aging in this neuroendocrine syndrome; ovarian aging may interact with neuroendocrine aging. Ovary-independent neuroendocrine changes occur as well. We also discuss developmental influences on adult aging in rodents and other examples in which adult lower mammals are sensitive to long lasting effects of steroids on the brain and pituitary. Possible molecular mechanisms are considered. In view of the long lasting effects of E2 and other steroids on lower mammals, the potential for long term effects of ovarian steroids on the human brain and pituitary warrants continued evaluation. Some Mammalian Aging processes involve effects of steroids on the brain and pituitary. An ovarydependent, neuroendocrine aging syndrome of laboratory rats and mice is described in this article. This syndrome can be attenuated during aging by chronic ovariectomy and can be prematurely induced in young rodents by sustained exposure to estradiol (E2). The limited follicular stock in the ovary is proposed to be a major pacemaker of aging in this neuroendocrine syndrome; ovarian aging may interact with neuroendocrine aging. Ovary-independent neuroendocrine changes occur as well. We also discuss developmental influences on adult aging in rodents and other examples in which adult lower mammals are sensitive to long lasting effects of steroids on the brain and pituitary. Possible molecular mechanisms are considered. In view of the long lasting effects of E2 and other steroids on lower mammals, the potential for long term effects of ovarian steroids on the human brain and pituitary warrants continued evaluation.
A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas
Authors: N. A. Mohile, L. E. Abrey, S. C. Lymberis, S. Karimi, B. L. Hou, P. H. Gutin
Journal: Journal of Clinical Oncology (2007)

2028 Background: Bevacizumab is a humanized monoclonal antibody directed at vascular endothelial growth factor A (VEGF-A). Preclinical studies suggest that inhibition of VEGF-A improves glioma response to radiotherapy. The concurrent use of bevacizumab and cranial radiotherapy has not been investigated. The objective of this study is to determine the safety of this combination. Methods: Patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytomas (AA) less than 3.5 cm received bevacizumab (10 mg/kg IV) every 2 weeks. MRI after cycle 1 (28 days) was done to reassess response and for RT planning. Patients then received stereotactic intensity modulated radiation therapy (IMRT): 30Gy in 5 fractions over 15 days. Bevacizumab treatment, given every 2 weeks, was administered during radiotherapy and continued until tumor progression. Brain MRI to assess response was performed after odd cycles. MR T1 and T2* perfusion were performed at baseline and after cycle 1. Results: 12 patients (10 GBM, 2 AA) with median age 53 (range, 30–61) and median KPS 90 (range, 80–100) received a median of 5.5 cycles of bevacizumab. In 1 patient, stereotactic IMRT could not be delivered safely to tumor. Grade III events occurred in 10 patients including hypertension, headache, seizures, neutropenia, hyponatremia and hypophosphatemia. There were no grade IV or V events, no dose limiting toxicities and no intracranial hemorrhage. 7/12 patients had objective responses (3 CR and 4 PR). In 5, SD was the best reported response. At last follow up, ten patients remain on study; 2 have come off for PD. Estimated 6 month PFS is 76%. MR perfusion imaging demonstrated a decrease in mean perfusion values after 1 cycle of bevacizumab. Conclusions: Bevacizumab in combination with RT is safe and well tolerated. Imaging responses and duration of disease control suggest that this regimen is active in this subset of recurrent glioma patients. Further investigations to determine efficacy and possible synergy of bevacizumab with radiotherapy are warranted. [Table: see text]
Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC)
Authors: D. R. Gandara, K. Yoneda, D. Shelton, L. A. Beckett, D. A. Ramies, J. Bloss, R. S. Herbst
Journal: Journal of Clinical Oncology (2006)

7071 Background: ILD is a rare but serious complication of EGFR tyrosine kinase inhibitor (TKI) therapy, fatal in about 1/3 of cases. The incidence, severity &amp; risk factors for ILD remain poorly understood, but it is reported to be more common in Asian patients receiving gefitinib. Whether the risk of ILD with gefitinib exceeds that of erlotinib is unclear. Whether concurrent chemotherapy increases the risk of ILD is also unclear. Methods: This study was designed to determine the incidence of ILD leading to death in 1,059 TRIBUTE patients randomized to chemotherapy plus erlotinib or placebo (Herbst: JCO, 2005). A blinded review of fatal SAEs was performed by an independent 3 person panel comprised of a medical oncologist (DRG), radiologist (DS), and pulmonologist (KY) unassociated with the study. Fatal respiratory SAEs (41 met criteria) were assigned to 1 of 4 potential attributions: progressive NSCLC; concurrent illness; toxicities not related to study drug; or ILD. Each panel member first made an independent assignation based on case report forms/source documents; then each case was discussed jointly. If needed, consensus was reached by vote. Results: Fatal SAEs were reported in 80/1059 patients (7.6%): 53/526 patients on erlotinib (10.1%) &amp; 27/533 on placebo (5.1%) (p = 0.002). Consensus assignation for 41 respiratory SAEs was as follows: NSCLC: 18 (44%), concurrent illness: 15 (37%), toxicities not related to study drug: 5 (12%), ILD: 3 (7%). There were no statistical differences in assignation by study arm. However, all 3 ILD cases occurred in the erlotinib arm (3/523; overall incidence 0.6%). Case details will be provided. Conclusions: 1) To our knowledge, this analysis of TRIBUTE is the only independent blinded assessment of respiratory SAEs &amp; ILD related to an EGFR TKI (erlotinib) + chemotherapy. 2) Overall, there were 41 fatal respiratory SAEs (3.9%). Fatal ILD occurred in 0.6% of cases treated with the combination. Using estimates that 1/3 of EGFR TKI-induced ILD cases are fatal, the overall incidence in this study arm was likely around 1.5–2%, not inconsistent with prior reports of TKIs alone. 3) Further studies designed to better define the underlying pathophysiology and risk factors for ILD are needed. [Table: see text]
Effect of guarana (<i>Paullinia cupana</i>) on fatigue in breast cancer patients undergoing systemic chemotherapy.
Authors: M. P. Campos, R. Riechelmann, L. C. Martins, B. J. Hassan, F. B. Casa, A. Del Giglio
Journal: Journal of Clinical Oncology (2010)

9007 Background: In breast cancer (BC) patients undergoing systemic chemotherapy, cancer-related fatigue (CRF) is a common problem that can negatively impact quality of life. Guarana Paullinia cupana is a plant native to the Amazon basin that has been used as a stimulant since pre-Columbian times. Purpose: To evaluate the effectiveness of guarana extract on fatigue, sleep quality, anxiety, depression symptoms, and menopause in a group of BC chemotherapy patients. Methods: Patients with progressive fatigue after their first cycle of chemotherapy were randomized to receive either guarana 50 mg by mouth twice daily (32 patients) or placebo (43 patients) for 21 days. After a 7-day wash-out period, patients were crossed over to the opposite experimental arm. All patients were evaluated on days 1, 21, and 49 using the FACIT F, FACIT-ES, Brief Fatigue Inventory (BFI), Pittsburgh Sleep Quality Index, Chalder Fatigue Scale, and Hospital Anxiety and Depression Scale (HADS). Results: Guarana significantly improved the FACIT-F, FACIT-ES and BFI global scores compared to placebo on days 21 and 49 (p < 0.01). The Chalder Scale improved significantly on day 21 (p = 0.002) but not on day 49 (p = 0.26). Guarana did not produce any CTCAE grades 3 or 4 toxicities and did not worsen sleep quality or cause anxiety or depression. Conclusions: Guarana is an effective, cheap and nontoxic alternative for the treatment of fatigue in BC patients receiving systemic chemotherapy. Further studies are needed to confirm our results and to evaluate their generalizability to other types of cancer. No significant financial relationships to disclose.
Amenorrhoea and galactorrhoea.
Authors: Dewhurst Cj
Journal: Journal of the Royal Society of Medicine (1973)

A recent study has shown the contraceptive pill to be the most important cause of amenorrhea and galactorrhea but the presence of a clear-cut cause should not be taken to exclude the possibility of additional causes especially pituitary  tumor. Galactorrhea is not always associated with secondary amenorrhea. Treatment with clomiphene and/or human gonadotrophin may make pregnancy possible.  Really troublesome galactorrhea has been successfully treated with .5 gm L-Dopa given every 6 hours;  successful treatment has also been reported with bromergocryptine an ergot alkaloid in doses from 3 to 9 mg/day.
Abstract 11429: Development of Spontaneous Myocarditis in Nuclear Factor kappa B (NF{kappa}B) p50-Deficient Mice: the Emerging Role of NF{kappa}B p65 in its Pathogenesis
Authors: Milan Gautam, Atsushi Izawa, Yuji Shiba, Yuchihiro Kashima, Jun Koyama, Minoru Hongo, Keji Sano, Takuma Hayashi, Motoki Ichikawa, Uichi Ikeda
Journal: Circulation (2012)

Background: The transcriptional factor NFκB plays a pivotal role in triggering inflammation and autoimmune responses. We observed spontaneous development of myocarditis in NFκB p50-deficient NOD mi...
Multifunctional Quantum Dot Nanoparticles for Effective Differentiation and Long‐Term Tracking of Human Mesenchymal Stem Cells In Vitro and In Vivo
Authors: Jinming Li, Wayne Yukwai Lee, Tianyi Wu, Jianbin Xu, Kunyu Zhang, Gang Li, Jiang Xia, Liming Bian
Journal: Advanced Healthcare Materials (2016)

Human mesenchymal stem cells (hMSCs) hold great potential for regenerative medicine. Efficient induction of hMSC differentiation and better understanding of hMSCs behaviors in vitro and in vivo are essential to the clinical translation of stem cell therapy. Here a quantum dots (QDs)‐based multifunctional nanoparticle (RGD‐β‐CD‐QDs) is developed for effective enhancing differentiation and long‐term tracking of hMSCs in vitro and in vivo. The RGD‐β‐CD‐QDs are modified with β‐cyclodextrin (β‐CD) and Cys‐Lys‐Lys‐Arg‐Gly‐Asp (CKKRGD) peptide on the surface. The β‐CD can harbor hydrophobic osteogenic small molecule dexamethasone (Dex) and the RGD peptide not only facilitates the complexation of siRNA and delivers siRNA into hMSCs but also leads to cellular uptake of nanoparticles by RGD receptor. Co‐delivery of Dex and siRNA by RGD‐β‐CD‐QDs nanocarrier significantly expedites and enhances the osteogenesis differentiation of hMSCs in vitro and in vivo by combined effect of small molecule and RNAi. Furthermore, the RGD‐β‐CD‐QDs can be labeled with hMSCs for a long‐term tracking (3 weeks) in vivo to observe the behaviors of implanted hMSCs in animal level. These findings demonstrate that the RGD‐β‐CD‐QDs nanocarrier provides a powerful tool to simultaneously enhance differentiation and long‐term tracking of hMSCs in vitro and in vivo for regenerative medicine.
Triose phosphate isomerase deficiency in 3 French families: two novel null alleles, a frameshift mutation (TPI Alfortville) and an alteration in the initiation codon (TPI Paris).
Authors: Colette Valentin, Serge Pissard, Josiane Martin, Delphine Héron, Philippe Labrune, Marie-Odile Livet, Michèle Mayer, Terri Gelbart, Arthur Schneider, Isabelle Max-Audit, Michel Cohen-Solal
Journal: Blood (2000)
Abstract 203: Visualization of drug delivery by using high resolution microscopic mass spectrometry
Authors: Masahiro Yasunaga, Masaru Furuta, Koretsugu Ogata, Yoshikatsu Koga, Yasuhiro Matsumura
Journal: Cancer Research (2015)

Abstract Pharmacokinetic (PK) and pharmacodynamic (PD) studies are important to evaluate the efficacy and toxicity of the drugs. In these analyses, tissue homogenates are generally used for the quantification by high-performance liquid chromatography (HPLC) or liquid chromatography mass spectrometry (LC-MS). However, they lack the information regarding the drug distribution in a specific anatomical area. The information of the drug distribution allows us to optimize the drug design enabling more efficient targeted delivery. We studied the tissue distribution of paclitaxel (PTX) and its micellar formulation (NK105) using a microscopic mass spectroscopy (MMS). A MMS in which a microscope is coupled with an atmospheric pressure matrix-assisted laser desorption/ionization (MALDI) and quadruple ion trap time-of-flight (TOF) analyser was used. The matrix-coated drug sample is ionised and then separated on the basis of its mass-to-charge ratio (m/z). Images were acquired from imaging mass spectrometry (IMS) or tandem mass spectrometry (MS/MS) data. (1) We established the drug imaging system with enhanced resolution and sensitivity. In the analysis, MS and MS/MS were used for quantification and validation, respectively. (2) NK105 showed much stronger antitumor effects on a human pancreatic cancer BxPC3 xenograft than PTX. In the drug imaging, we demonstrated that NK105 delivered more PTX to the whole tumor tissue (including the center lesion). In the mouse model, PTX caused the peripheral neurotoxicity but NK105 did not. Multiple high drug-signal areas surrounding and inside the caudal nerve were observed in the case of PTX, whereas the signals after NK105 injection were significantly low. We succeeded in visualising the EPR (Enhanced Permeability and Retention) effect using MMS. The data obtained by the drug imaging may be useful for facilitating DDS-drug design. The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. Sci Rep. 3:3050. 2013. Citation Format: Masahiro Yasunaga, Masaru Furuta, Koretsugu Ogata, Yoshikatsu Koga, Yasuhiro Matsumura. Visualization of drug delivery by using high resolution microscopic mass spectrometry. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 203. doi:10.1158/1538-7445.AM2015-203
The changes in quality of life during the palliative chemotherapy for solid cancer
Authors: S.-M. Bang, S. H. Park, H. G. Kang, J.-S. Im, I. H. Cho, E. K. Cho, D. B. Shin, J. H. Lee
Journal: Journal of Clinical Oncology (2004)

8237 Background: We conducted this prospective study to assess the changes of quality of life, anxiety and depression in patients receiving palliative chemotherapy for solid cancers. Methods: Patients with histologically confirmed metastatic or relapsed cancer, life expectancy of more than 6 months and the ability to fill-up questionnaires by oneself were eligible. The effect of chemotherapy on quality of life and the levels of their anxiety and depression were assessed at baseline and after every 3 cycles of chemotherapy, by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and Hospital Anxiety and Depression Scale (HADS). Results: Between July 2001 and October 2003, 146 patients were entered onto the protocol. Ninety-eight patients completed the questionnaire and 46 patients withdrew from trial (27 for lost follow-up, 11 for withdrawal of consents, 5 for toxicity, 5 for progression). Their median age was 58 years old (range 28–78) and male to female ratio was 1.6. Chemotherapy was administered as the first, second, and third or more line in 107, 29, and 10 patients respectively (including 52 cases of gastric cancer, 39 of non-small cell lung cancer, 29 of colorectal cancer, 11 of breast cancer, and 15 of others). Compared with baseline, clinically meaningful relief (score decreased more than 10) of symptoms such as pain, dyspnea, and sleep disturbance was observed. There was significant improvement (score increased more than 10) of the functioning scales after the first cycle of chemotherapy, but these effects didn't persist through the whole course of therapy. The incidence of probable anxiety and depression disorder before the chemotherapy were 20% and 29% each. The anxiety scores decreased throughout the whole period of intervention (p<0.01). Pre-treatment anxiety and depression were negatively correlated with baseline QOL scores. Conclusions: The palliative chemotherapy in patients with solid cancer improved the cancer-related symptoms and lessened the anxiety. Also it did not disturb the function and overall quality of life. No significant financial relationships to disclose.